```
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:15:03 ON 03 DEC 2005

=> file reg
=>Uploading C:\Program Files\Stnexp\Queries\10521821.str

L1      STRUCTURE UPLOADED

=> dis l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sam
L2           10 SEA SSS SAM L1

=> s l1 full
L3          224 SEA SSS FUL L1

=> file caplus
=> s l3
L4            2 L3

=> s l4 and pd<april 2003
      23567838 PD<APRIL 2003
                 (PD<20030400)
L5            0 L4 AND PD<APRIL 2003

=> dis l4 1-2 bib abs

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2004:964996  CAPLUS
DN   141:406037
TI   Heterocyclic compound inhibitors of Akt kinase activity, and use for the
     treatment of cancer
IN   Bilodeau, Mark T.; Wu, Zhicai
PA   Merck & Co., Inc., USA
SO   PCT Int. Appl., 62 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
PI   WO 2004096130        A2    20041111    WO 2004-US12187         20040420
     WO 2004096130        A3    20050407
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
```

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-465123P P 20030424
OS MARPAT 141:406037
GI



I

AB The invention discloses compds. which contain a five-membered heterocyclic ring fused to a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention further discloses chemotherapeutic compns. containing the compds. of the invention and methods for treating cancer comprising administration of the compds. of the invention. Preparation of compds., e.g. I, is described.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:120677 CAPLUS
DN 140:163855
TI Preparation of substituted furo[2,3-b]pyridines as antagonists and/or inverse agonists of cannabinoid-1 receptor with therapeutic uses
IN Toupence, Richard B.; Debenham, John S.; Goulet, Mark T.; Madsen-Duggan, Christina B.; Walsh, Thomas F.; Shah, Shrenik K.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004012671	A2	20040212	WO 2003-US24280	20030801
	WO 2004012671	A3	20050609		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2494091 AA 20040212 CA 2003-2494091 20030801
EP 1558252 A2 20050803 EP 2003-767117 20030801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2002-400852P P 20020802
US 2003-456332P P 20030320
WO 2003-US24280 W 20030801
OS MARPAT 140:163855
GI



I



II

AB Novel furopyridines (shown as I; variables defined below; e.g. II) are antagonists and/or inverse agonists of the cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compds. of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compds. are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. Although the methods of preparation are not claimed, .apprx.200 example prepns. are included. For example, II was prepared in 3 steps starting by condensing 4-chlorobenzyl 2,4-dichlorophenyl ketone with DMF di-Me acetal in DMF to give 3-dimethylamino-1-(2,4-dichlorophenyl)-2-(4-chlorophenyl)prop-2-en-1-one followed by cyclocondensation with 2-cyanoacetamide and methanol in DMF to give 6-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-2-oxo-1,2-dihydropyridine-3-nitrile followed by cyclization with 2-chloroacetophenone and Cs2CO3 in DMF. For I: R1 = C1-10alkyl, C2-10alkenyl, C2-10alkynyl, -CN, -COR4, -S(O)mR4, -S(O)2NH(CO)nNRe, cycloheteroalkyl, aryl, and heteroaryl; R2 = H, -NR5R6, -COR4, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, aryl, arylC1-6alkyl, arylC2-6alkenyl, heteroaryl, heteroarylC1-6alkyl, heteroarylC2-6alkenyl, cycloheteroalkyl, hydroxy, and ORg; R3 = H, C1-6alkyl, C1-6alkyloxy, trifluoromethyl,

trifluoromethoxy, halo, and C3-7cycloalkyl; Ar1 and Ar2 = aryl, heteroaryl; addnl. details are given in the claims. CB1 antagonist/inverse agonist compds. I have IC50s of <1 μM in the CB 1 binding assay; selective CB 1 antagonist/inverse agonist compds. have IC50s 100-fold greater in the CB2 binding assay than in the CB1 assay, and generally have IC50s of ≥1 μM in the CB2 binding assay. CB1 antagonist/inverse agonist compds. I generally have EC50s of <1 μM in the CB1 functional assay and selective CB1 antagonist/inverse agonists generally have EC50s of >1 μM in the CB2 functional assay. IC50 and/or EC50 values are not given for specific examples of I.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.64	169.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.46	-1.46

STN INTERNATIONAL LOGOFF AT 13:16:26 ON 03 DEC 2005